Back
Akebia Therapeutics, Inc. 10K Form
Sell
35
AKBA
Akebia Therapeutics, Inc.
Last Price:
$1.60
Seasonality Move:
43.42%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive AKBA News And Ratings
See the #1 stock for the next 7 days that we like better than AKBA
AKBA Financial Statistics
Sales & Book Value
| Annual Sales: | $160.2M |
|---|---|
| Cash Flow: | $28M |
| Price / Cash Flow: | 12.43 |
| Annual Sales: | $0.16 |
| Price / Book: | 10.14 |
Profitability
| EPS (TTM): | -0.07610 |
|---|---|
| Net Income (TTM): | $-15.9M |
| Gross Margin: | $91.3M |
| Return on Equity: | 0% |
| Return on Assets: | -5.49% |
Akebia Therapeutics, Inc. Earnings Forecast
Key Akebia Therapeutics, Inc. Financial Ratios
-
The Gross Profit Margin over the past 12 years for AKBA is 57.03%.
-
The Selling, General & Administrative Expenses for AKBA have been equal to 68.53% of Gross Profit Margin.
-
The Research & Development expenses have been 19.97% of Revenue.
-
The Net Earning history of AKBA is -43.33% of Total Revenues.
-
Per Share Earnings over the last 13 years have been positive in 6 years.
Akebia Therapeutics, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | AKBA |
| CUSIP: | 00972D |
| Website: | akebia.com |
Debt
| Debt-to-Equity Ratio: | 5.13 |
|---|---|
| Current Ratio: | 1.94 |
| Quick Ratio: | 1.76 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 9.35 |
AKBA Technical Analysis vs Fundamental Analysis
Sell
35
Akebia Therapeutics, Inc. (AKBA)
is a Sell
Is Akebia Therapeutics, Inc. a Buy or a Sell?
-
Akebia Therapeutics, Inc. stock is rated a SellThe current Akebia Therapeutics, Inc. [AKBA] share price is $1.59. The Score for AKBA is 35, which is 30% below its historic median score of 50, and infers higher risk than normal.